Cardiac steatosis associates with visceral obesity in nondiabetic obese men

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 1189-1197

  Granér, Marit ^a   Siren, Reijo ^b   Nyman, Kristofer ^b   Lundbom, Jesper ^b   Hakkarainen, Antti ^b   Pentikäinen, Markku O ^a   Lauerma, Kirsi ^b   Lundbom, Nina ^b   Adiels, Martin ^c   Nieminen, Markku S ^a   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIAC STEATOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPICARDIAL FAT; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; METABOLIC SYNDROME X; OBESITY; PERICARDIAL FAT; PRIORITY JOURNAL; RISK FACTOR; VISCERAL OBESITY; WAIST CIRCUMFERENCE;

ADULT; CHOLESTEROL; FEMALE; HEART DISEASES; HOMEOSTASIS; HUMANS; INTRA-ABDOMINAL FAT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PERICARDIUM; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TRIGLYCERIDES;

EID: 84874868379     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3190     Document Type: Article

References (40)

1. Poirier P, Giles TD, Bray GA, et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
2. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-1132.
3. Cornier MA, Marshall JA, Hill JO, Maahs DM, Eckel RH. Prevention of overweight/obesity as a strategy to optimize cardiovascular health. Circulation. 2011;124:840-850.
4. Coutinho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011;57:1877-1886.
5. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28:1039-1049.
6. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. Circ J. 2009;73:27-34.
7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. (Pubitemid 40523737)
8. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417-423. (Pubitemid 36262808)
9. Kellman P, Hernando D, Arai AE. Myocardial fat imaging. Curr Cardiovasc Imaging Rep. 2010;3:83-91.
10. Kankaanpää M, Lehto HR, Pärkkä JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab. 2006;91:4689-4695. (Pubitemid 44833458)
11. Iozzo P, Lautamaki R, Borra R, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab. 2009;94:4472-4482.
12. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175. (Pubitemid 47360218)
13. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-1799.
14. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101:759-767. (Pubitemid 350287190)
15. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-319.
16. Szendroedi J, Roden M. Ectopic lipids and organ function. Curr Opin Lipidol. 2009;20:50-56.
17. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab. 2010;298:E897-E908.
18. Després JP. Body fat distribution and risk of cardiovascular disease. An update. Circulation. 2012;126:1301-1313.
19. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of obesity. Circulation. 2009;120:1640-1645.
20. Mente A, Yusuf S, Islam S, et al. INTERHEART Investigators. Metabolic syndrome and risk of acute myocardial infarction a casecontrol study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55:2390-2398.
21. Bayturan O, Tuzcu EM, Lavoie A, et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med. 2010;170:478-484.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004;27:1487-1495.
24. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantification of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med. 2001;31:269-286. (Pubitemid 32378728)
25. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35-43. (Pubitemid 127454051)
26. Westerbacka J, Corner A, Tiikkainen M, et al. Womenandmenhave similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360-1369. (Pubitemid 39232420)
27. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of nonalcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-872.
28. Szcepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462-E468. (Pubitemid 40110657)
29. Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55:2622-2630.
30. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
31. Sicari R, Sironi AM, Petz R, et al. Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study.J Am Soc Echocardiogr. 2011;24:1156-1162.
32. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450-457.
33. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care. 2011;34:S371-S379.
34. Gaborit B, Kober F, Jacquier A, et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes. 2012;36:422-430.
35. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92:10-18.
36. Bharadwaj KG, Hiyama Y, Hu Y, et al. Chylomicron- and VLDL derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem. 2010;285:37976-37986.
37. Perman JC, Boström P, Lindbom M, et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest. 2011;121:2625-2640.
38. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765. (Pubitemid 43357551)
39. Liu CY, Redheuil A, Ourwerkerk R, Lima JA, Bluemke DA. Myocardial fat quantification in humans: evaluation by two-point waterfat imaging and localized proton spectroscopy. Magn Reson Med. 2010;63:892-901.
40. Utz W, Engeli S, Haufe S, et al. Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women. Heart. 2011;97:1585-1589.